MRK vs VRT: Which Is the Better Buy?

Side-by-side comparison of Merck & Co., Inc. and Vertiv Holdings Co — fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-06-20.
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D High Quality
VS
Vertiv Holdings Co · Industrials
$333.05
-45.0% upside to fair value
Grade D High Quality
QuantHub Verdict
MRK has more upside to fair value (-12.1%). MRK trades at a lower forward P/E (32.0x). These are model outputs — not personalized investment advice. See all research →
Valuation & Fundamentals
Metric MRK VRT
Current Price $113.87 $333.05
Fair Value Estimate $100.14 $183.18
Upside to Fair Value -12.1% -45.0%
Market Cap $281.2B $127.9B
Forward P/E 32.0x 81.8x
EV / EBITDA 17.3x 55.4x
Price / Sales 4.3x 11.8x
Price / FCF 19.9x 55.4x
Revenue Growth YoY +4.3% +30.1%
Gross Margin 75.9% 36.2%
Operating Margin 27.6% 18.5%
Return on Equity 17.9% 42.1%
Dividend Yield 0% 0%
FCF Yield 5.02% 1.81%
Analyst Consensus Hold Strong Buy
Investment Thesis
MRK — Merck & Co., Inc.
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
VRT — Vertiv Holdings Co
Vertiv Holdings Co operates in the industrials sector, specializing in electrical equipment and parts with a strong focus on data center critical infrastructure. The company benefits from a durable competitive position supported by a broad product portfolio that drives approximately 75% of sales from data centers. Vertiv's business quality is high, demonstrated by a 42.1% return on equity, strong…
Accumulation Zones
Metric MRK VRT
Zone Low $75.11 $137.38
Zone High $85.12 $155.70
In Buy Zone? No No
← MRK Research    VRT Research →    All Research